Treceți offline cu aplicația Player FM !
Podcasturi care merită ascultate
SPONSORIZAT
![<div class="span index">1</div> <span><a class="" data-remote="true" data-type="html" href="/series/from-creative-passion-to-profit">From Creative Passion To Profit</a></span> podcast artwork](https://cdn.player.fm/images/54246369/series/tBc6icen2GmDMA2n/32.jpg 32w, https://cdn.player.fm/images/54246369/series/tBc6icen2GmDMA2n/64.jpg 64w, https://cdn.player.fm/images/54246369/series/tBc6icen2GmDMA2n/128.jpg 128w, https://cdn.player.fm/images/54246369/series/tBc6icen2GmDMA2n/256.jpg 256w, https://cdn.player.fm/images/54246369/series/tBc6icen2GmDMA2n/512.jpg 512w)
![<div class="span index">1</div> <span><a class="" data-remote="true" data-type="html" href="/series/from-creative-passion-to-profit">From Creative Passion To Profit</a></span> podcast artwork](/static/images/64pixel.png)
03_05 NSCLC metastatic without driver mutations
Manage episode 366702187 series 3335024
1. Evidence to support platinum doublets
2. The tale of pemetrexed
3. Immune checkpoint inhibitors alone and in combination
4. Second Line, approach in progression
Citations
As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.
DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.
Uptodate.com Waltham, MA: Wolters Kluwer.
1. Paz-Ares L et al. Lancet Oncol. 2021;22(2):198-211. doi:10.1016/S1470-2045(20)30641-0
2. Hellmann MD et al. NEJM. 2019;381(21):2020-2031. doi:10.1056/NEJMOA1910231
3. Socinski MA et al. J Thorac Oncol. 2021;16(11):1909-1924. doi:10.1016/J.JTHO.2021.07.009
4. Reck M et al. NEJM. 2016;375(19):1823-1833. doi:10.1056/NEJMOA1606774
5. Paz-Ares L et al. NEJM. 2018;379(21):2040-2051. doi:10.1056/NEJMOA1810865
6. Gandhi L et al. NEJM. 2018;378(22):2078-2092. doi:10.1056/NEJMOA1801005/
7. Scagliotti G et al. Oncologist. 2009;14(3):253-263. doi:10.1634/THEONCOLOGIST.2008-0232
8. Paz-Ares L et al. Lancet Oncol. 2012;13(3):247-255. doi:10.1016/S1470-2045(12)70063-3
9. Paz-Ares LG et al. JCO. 2013;31(23):2895-2902. doi:10.1200/JCO.2012.47.1102
10. Scagliotti GV et al. JCO. 2008;26(21):3543-3551. doi:10.1200/JCO.2007.15.0375
11. Delbaldo C et al. JAMA. 2004;292(4):470-484. doi:10.1001/JAMA.292.4.470
12. Ardizzoni A et al. J Natl Cancer Inst. 2007;99(11):847-857. doi:10.1093/JNCI/DJK196
13. Temel JS et al. NEJM. 2010;363(8):733-742. doi:10.1056/NEJMOA1000678
Disclosures
Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.
Tags
Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology
49 episoade
03_05 NSCLC metastatic without driver mutations
Talking About Tumors with Ryann and Ryan - A medical oncology podcast
Manage episode 366702187 series 3335024
1. Evidence to support platinum doublets
2. The tale of pemetrexed
3. Immune checkpoint inhibitors alone and in combination
4. Second Line, approach in progression
Citations
As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.
DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.
Uptodate.com Waltham, MA: Wolters Kluwer.
1. Paz-Ares L et al. Lancet Oncol. 2021;22(2):198-211. doi:10.1016/S1470-2045(20)30641-0
2. Hellmann MD et al. NEJM. 2019;381(21):2020-2031. doi:10.1056/NEJMOA1910231
3. Socinski MA et al. J Thorac Oncol. 2021;16(11):1909-1924. doi:10.1016/J.JTHO.2021.07.009
4. Reck M et al. NEJM. 2016;375(19):1823-1833. doi:10.1056/NEJMOA1606774
5. Paz-Ares L et al. NEJM. 2018;379(21):2040-2051. doi:10.1056/NEJMOA1810865
6. Gandhi L et al. NEJM. 2018;378(22):2078-2092. doi:10.1056/NEJMOA1801005/
7. Scagliotti G et al. Oncologist. 2009;14(3):253-263. doi:10.1634/THEONCOLOGIST.2008-0232
8. Paz-Ares L et al. Lancet Oncol. 2012;13(3):247-255. doi:10.1016/S1470-2045(12)70063-3
9. Paz-Ares LG et al. JCO. 2013;31(23):2895-2902. doi:10.1200/JCO.2012.47.1102
10. Scagliotti GV et al. JCO. 2008;26(21):3543-3551. doi:10.1200/JCO.2007.15.0375
11. Delbaldo C et al. JAMA. 2004;292(4):470-484. doi:10.1001/JAMA.292.4.470
12. Ardizzoni A et al. J Natl Cancer Inst. 2007;99(11):847-857. doi:10.1093/JNCI/DJK196
13. Temel JS et al. NEJM. 2010;363(8):733-742. doi:10.1056/NEJMOA1000678
Disclosures
Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.
Tags
Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology
49 episoade
Tous les épisodes
×![Artwork](/static/images/128pixel.png)
1 05_01 Hepatocellular carcinoma 32:13
![Artwork](/static/images/128pixel.png)
1 04_08 Metastatic Renal Cell Carcinoma 24:16
![Artwork](/static/images/128pixel.png)
1 04_07 Localized Renal Cell Carcinoma 25:15
![Artwork](/static/images/128pixel.png)
1 04_06 Metastatic Urothelial Cancer 24:33
![Artwork](/static/images/128pixel.png)
1 04_05 Muscle Invasive Bladder Cancer 29:16
![Artwork](/static/images/128pixel.png)
1 01_14 Ampullary Carcinoma (Mini Discussion) 10:59
![Artwork](/static/images/128pixel.png)
1 04_04 Castrate Resistant Metastatic Prostate Cancer 24:50
![Artwork](/static/images/128pixel.png)
1 04_03 Metastatic Castrate Sensitive Prostate Cancer 29:02
![Artwork](/static/images/128pixel.png)
1 04_02 Adjuvant Options for Prostate Cancer 28:41
![Artwork](/static/images/128pixel.png)
1 04_01 Fundamentals of Localized Prostate Cancer 31:59
![Artwork](/static/images/128pixel.png)
1 03_13 Head and Neck Cancer – Locally advanced and metastatic 37:18
![Artwork](/static/images/128pixel.png)
1 03_12 Head and Neck Cancer – Background and adjuvant considerations 23:28
![Artwork](/static/images/128pixel.png)
1 03_11 Mesothelioma and a bit of Large Cell Neuroendocrine Carcinoma 29:40
Bun venit la Player FM!
Player FM scanează web-ul pentru podcast-uri de înaltă calitate pentru a vă putea bucura acum. Este cea mai bună aplicație pentru podcast și funcționează pe Android, iPhone și pe web. Înscrieți-vă pentru a sincroniza abonamentele pe toate dispozitivele.